Michael A. Metzger - 30 Sep 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Executive Officer, Director
Signature
/s/ Michael A. Metzger
Issuer symbol
SNDX
Transactions as of
30 Sep 2022
Net transactions value
-$548,736
Form type
4
Filing time
04 Oct 2022, 17:49:19 UTC
Previous filing
27 Jul 2022
Next filing
07 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $259,645 +29,606 +168% $8.77 47,265 30 Sep 2022 Direct
transaction SNDX Common Stock Sale $740,757 -29,606 -63% $25.02 17,659 30 Sep 2022 Direct F1, F2
transaction SNDX Common Stock Options Exercise $25,284 +2,883 +16% $8.77 20,542 03 Oct 2022 Direct
transaction SNDX Common Stock Sale $72,107 -2,883 -14% $25.01 17,659 03 Oct 2022 Direct F1, F3
transaction SNDX Common Stock Options Exercise $11,226 +1,280 +7.2% $8.77 18,939 04 Oct 2022 Direct
transaction SNDX Common Stock Sale $32,026 -1,280 -6.8% $25.02 17,659 04 Oct 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -29,606 -100% $0.000000* 0 30 Sep 2022 Common Stock 29,606 $8.77 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -2,883 -100% $0.000000* 0 03 Oct 2022 Common Stock 2,883 $8.77 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -1,280 -100% $0.000000* 0 04 Oct 2022 Common Stock 1,280 $8.77 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 690,759 options to purchase shares of common stock that are vested and immediately exercisable and a total of 485,001 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $25.00 to $25.15.
F3 The sale prices ranged from $25.00 to $25.03.
F4 This option is fully vested.